Babraham Research Campus: Fifteen to Fifty


With the first commercial tenant at the Babraham Research Campus in 1998, Babraham Bioscience Technologies (BBT) Limited celebrates its fifteenth anniversary this year.

Another milestone was reached when the Campus welcomed its fiftieth tenant Cambridge Epigenetix (CEGX), a Cambridge University spin-out that aims to be the world leading provider of high quality, easy to use epigenetic tools.

Dr Tony Smith, Chief Technical Officer for CEGX, says "We are delighted to be moving to Babraham Research Campus and are excited about the excellent facilities it offers and the potential interactions with the Centre of Excellence in Epigenetics”.

BBT also opened its latest facility the Jonas Webb building which is now home to Cancer Research Technologies, Sphere Fluidics, Biosceptre as well as Cambridge Epigenetix.  In addition other new tenant companies joining the campus this year were ABeterno, Axol Bioscience, Camstent, Cambimune, CCCR Cambridge, Definigen, RXCelerate, X01 and SynMed Chem.  Johnson & Johnson Innovation also recently announced the opening of an out-reach office on the Campus as extensions of its London Innovation Centre to work with academics and entrepreneurs in the Cambridge area.  The Centre for Process Innovation have also setup a partnering office on site.

Babraham’s Bio-incubator was established in 1998 and provides bespoke accommodation for early stage biomedical companies and support during their formative years.  Over 95 companies have benefitted from the exceptional in-house services, access to state of the art office and laboratory space and the renowned interaction with the world leading Babraham Institute.  With a further building due to be opened in 2014 as a result of the investment of £44M from the BBSRC,  BBT hopes to continue to support the world-leading biomedical research developed in the Cambridge area.

Derek Jones, Chief Executive, said, “This has been a great year for the Campus.  We are delighted to now have fifty organisations on site, helping to discover and develop future therapies.  Our facilities and capabilities are not just for those on the campus, but are available for others to access. As well as our tenants we will continue to work with the wider biomedical community through events such as our annual bio-investment forum, and with local organisations such as Medimmune, Pfizer, Cambridge Enterprise and One Nucleus.”

To read more information, click here.

Babraham Bioscience Technologies Ltd (BBT) is responsible for the commercial development of the Babraham Research Campus. The Babraham Research Campus is distinct in its co-location of bioscience companies with the Babraham Institute, a world-renowned research organisation. The Campus provides companies laboratory and office space together with access to outstanding scientific facilities in an ideal geographical location at the core of the Cambridge cluster.

Babraham Research Campus Ltd.